Efficacy and Safety of Glecaprevir/Pibrentasvir in Children Aged 3–11 Years With Chronic Hepatitis C: A Real‐World, Prospective, Multicenter Study in Japan

Documenti analoghi

• Natural history and clinical features of hepatitis C virus infection during childhood: A nationwide, observational survey in Japan
  di: Satoshi Nakano, et al.
  Pubblicazione: (2024)
• Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C
  di: Seiichi Tawara, et al.
  Pubblicazione: (2026)
• Successful Retreatment of Glecaprevir‐Pibrentasvir for Hepatitis C Virus Genotype 2a Infection in Patient Whose Cirrhosis Improved From Decompensation to Compensation After Sofosbuvir–Velpatasvir Therapy
  di: Tatsuo Kanda, et al.
  Pubblicazione: (2025)
• Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs
  di: Takanori Suzuki, et al.
  Pubblicazione: (2024)
• Serum alpha‐fetoprotein/hepatocyte growth factor ratio as a novel biomarker predicting the prognosis of acute alcoholic hepatitis
  di: Hiroki Inada, et al.
  Pubblicazione: (2025)